Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855562) titled 'MPS IIIA Disease Monitoring Program' on Sept. 25.

Study Type: Observational

Primary Sponsor: Ultragenyx Pharmaceutical Inc

Condition: MPS IIIA Sanfilippo Syndrome Sanfilippo A Mucopolysaccharidosis III

Intervention: Other: No Intervention

Recruitment Status: Not recruiting

Date of First Enrollment: November 2026

Target Sample Size: 55

To know more, visit https://clinicaltrials.gov/study/NCT07855562

Disclaimer: Curated by HT Syndication....